

1 **Brainstem somatostatin-expressing cells control the emotional** 2 **regulation of pain behavior**

3
4 Nanci Winke^{§1,2}, Frank Aby^{§3}, Daniel Jercog^{§1,2}, Grivet Zoé³, Delphine Girard^{1,2}, Marc Landry³,
5 Laia Castell⁴, Emmanuel Valjent⁴, Stephane Valerio^{*1,2}, Pascal Fossat^{*3} and Cyril Herry^{*1,2}

6
7 ¹*Univ. Bordeaux, Neurocentre Magendie, U1215, 146 Rue Léo-Saignat, 33077 Bordeaux, France*

8 ²*INSERM, Neurocentre Magendie, U1215, 146 Rue Léo-Saignat, 33077 Bordeaux, France.*

9 ³*Institut des maladies neurodégénératives (IMN, CNRS UMR 5293), 146 Rue Léo-Saignat, 33077 Bordeaux, France.*

10 ⁴*IGF, Montpellier, CNRS, INSERM, 34094 Montpellier, France.*

11

12 § shared authorship

13 * shared seniority

14 **Abstract**

15

16 **In mammals, threat-related behavior is typically induced by a noxious physical stressor and**
17 **is associated with a broad range of behavioral responses such as freezing and avoidance.**
18 **These behavioral responses are associated with the regulation of pain responses allowing**
19 **individuals to cope with noxious stimuli. Whereas the structures and mechanisms involved**
20 **in pain behavior are well documented, little is known about the precise neuronal circuits**
21 **mediating the emotional regulation of pain behavior. Here we used a combination of**
22 **behavioral, anatomical, optogenetic, and electrophysiological approaches to show that**
23 **somatostatin-expressing neurons in the ventrolateral periaqueductal gray matter (vlPAG**
24 **SST cells) promote antinociceptive responses during the presentation of conditioned stimuli**
25 **(CS) predicting footshocks. Whereas the optogenetic inhibition of vlPAG SST cells during**
26 **CS presentation promoted analgesia, their optogenetic activation reduced analgesia by**
27 **potentiating pain responses in the spinal cord through a relay in the rostral ventromedial**
28 **medulla (RVM). Together these results identify a brainstem circuit composed of vlPAG SST**

29 **cells specifically projecting to the RVM and mediating fear conditioned analgesia (FCA) to**
30 **regulate pain responses during threatful situations.**

31

32 **Introduction**

33 Displaying adaptive behavioral responses to threat-predicting stimuli is a fundamental process
34 allowing mammals to survive. This process critically depends on the ability of mammals to
35 associate specific cues with their harmful consequences and establish long-lasting predictions
36 about future aversive outcomes. Freezing and avoidance are among the most studied behavioral
37 responses in response to specific threat-predicting cues and are associated with a simultaneous
38 regulation of pain responses allowing accurate behavioral responses¹. Indeed, it is now widely
39 accepted that specific threats can modulate pain processing through either a reduction (analgesia)
40 or an increase (hyperalgesia) of pain sensitivity in case of acute and chronic threat exposure,
41 respectively²⁻⁴. Moreover, recent reports in humans revealed a strong comorbidity between anxiety-
42 related disorders and pain-related disorders⁵, suggesting that the deregulation of the neuronal
43 circuits controlling pain processing could lead to the development of anxiety-related pathology. In
44 addition, there is also a strong overlap between the neuronal structures mediating aversive learning
45 and pain processing, including the medial prefrontal cortex (mPFC) and the periaqueductal grey
46 (PAG), two central structures in fear and pain modulation⁶⁻⁹. An interesting model to study the
47 emotional regulation of pain behavior is FCA², in which a fearful event can lead to a reduction in
48 pain sensitivity. Because the PAG is a midbrain structure receiving many cortical and subcortical
49 inputs from structures involved in fear processing¹⁰⁻¹² and projecting to the spinal cord through a
50 brainstem relay in the rostral ventromedial medulla⁶ (RVM), it is ideally located to allow the
51 emotional regulation of pain behavior. The ventrolateral part of the PAG (vIPAG) is crucial for the

52 descending control of pain in the dorsal horn of the spinal cord⁶ (DH), and several reports indicated
53 that electrical stimulation of the vIPAG selectively inhibits responses to noxious stimuli in a variety
54 of pain test conditions^{6,8,13-15}. Moreover, it has been documented that analgesia induced upon
55 vIPAG stimulation is opioid-dependent^{16,17} and involves direct descending projections to the RVM
56 and the DH. In addition, recent data indicated that vIPAG activation induces analgesia through the
57 recruitment of local GABAergic neurons, which is consistent with our knowledge on the role of
58 the GABAergic system in the descending control of pain^{9,13,18}. However, to date, the precise
59 neuronal elements and circuits involved in FCA at the level of the vIPAG are still largely unknown.

60

61 **Results**

62 **FCA depends on associative learning**

63 To evaluate the contribution of specific vIPAG cells in the emotional modulation of pain
64 behavior, we developed a novel fear conditioned analgesia (FCA) procedure during which mice
65 were first submitted to a discriminative auditory fear conditioned paradigm followed by a pain
66 sensitivity assay (**Figure 1a**). In this paradigm, an initially neutral stimulus (the conditioned
67 stimulus, CS) is associated with a mild coincident aversive footshock (the unconditioned stimulus,
68 US). Twenty-four hours following conditioning, re-exposure to CS associated with the US (CS⁺),
69 but not to the control non-conditioned CS (CS⁻) promoted freezing behavior, which we used as a
70 behavioral fear readout (**Figure 1a, b and Supplementary Figure 1a, b**). Following the fear
71 retrieval session, mice were exposed to a hot plate test session (HP) in which the basal plate
72 temperature was progressively increased (6°C per min), and paired with either the CS⁻ or the CS⁺
73 presentation until mice display a classical nociception response (**Supplementary Figure 1d**,
74 **Material and Methods**). The CS⁻ and CS⁺ presentation order was counterbalanced across animals.

75 Interestingly, mice exposed to the CS⁺ in the HP test exhibited a significant delay in the
76 nociceptive response compared to CS⁻ exposure, which reflected the development of a CS-specific
77 analgesic response (**Figure 1c and Supplementary Figure 1c**).

78 To control that FCA was due to fear associative processes and not merely sensory processing of
79 the CSs, several controls were performed. First, naïve mice were submitted to the HP test without
80 CSs presentation (**Supplementary Figure 2a**). This test allowed us to measure the basal
81 nociceptive response during the increasing-temperature HP test. Another group of naïve mice were
82 submitted to the HP test with CSs presentations where the CS-US association was never reinforced
83 (**Supplementary Figure 2a**). In both conditions, we failed to observe any analgesic responses
84 (**Supplementary Figure 2c-d**). Second, mice were fear conditioned and tested in the HP test
85 without CS presentations, a condition in which we observed analgesia (**Supplementary Figure**
86 **2a-c**). Next, a subset of conditioned mice was submitted to an extinction procedure consisting of
87 24 non-reinforced exposures to the CS⁺, which lead to complete inhibition of conditioned fear
88 responses (**Figure 1d, e**). As expected, extinguished mice exposed to the HP test failed to exhibit
89 FCA responses during CS⁺ presentations. (**Figure 1f, g, and Supplementary Figure 2e**). Together
90 these data indicate that FCA depends on associative processes and does not rely on sensory
91 processing of the CS.

92 Furthermore, the FCA responses observed upon CS⁺ exposure in the HP test were stable upon
93 multiple exposures to the HP test (**Supplementary Figure 3a-e**) and not due to a competition with
94 freezing responses evoked by the CS⁺ as mice did not freeze before the nociceptive response
95 (**Supplementary Figure 1d, e**).

96 The use of thermal nociception test in FCA has been reported to lead to possible erroneous
97 interpretations. Indeed, the fearful stimulus can lead to vasoconstriction¹⁷ which could result from
98 a redirection of the blood flow to the skeletal musculature, thus decreasing the temperature in the

99 extremities of the body. If so, this phenomenon by itself could explain the delay observed for the
100 nociceptive response during CS⁺. To further evaluate this possibility, we monitor changes in the
101 back and tail temperature of mice submitted to the HP during CS⁻ and CS⁺ presentations without
102 increasing the temperature of the HP device (**Supplementary Figure 3f-h**). Our results did not
103 reveal any difference in tail or back temperature between CS⁻ and CS⁺ presentations, thereby ruling
104 out a potential vasoconstriction effect that could explain our results.

105

106 **Inhibition of vIPAG SST cells mediate FCA**

107 Previous publications indicated that the ventrolateral PAG (vIPAG) is a critical region involved
108 in analgesia^{8,9,14,15}. To identify the cell types in the vIPAG mediating our analgesic effect in the
109 FCA task, we focused on GABAergic neurons, which activity are supposed to be inhibited during
110 analgesia through a μ -opioid receptor-dependent (MOR) mechanism^{6,13,16}. Because somatostatin-
111 expressing interneurons (SST) are the most abundant inhibitory cell class in the PAG¹⁹, we focused
112 on this cell population. We first evaluated the expression of *Sst* mRNAs in excitatory and inhibitory
113 cell populations in the PAG of SST-Cre mice using single-molecule fluorescent in situ
114 hybridization (smFISH, **see Methods**). Our results indicated that *Sst* mRNAs were expressed in
115 both the dorsal PAG (dIPAG) and ventral PAG (vIPAG) with a high specificity (percent of *Sst*⁺
116 cells among *Cre*⁺ cells: dIPAG: 94%; vIPAG: 88%) and sensitivity (percent of *Cre*⁺ cells among
117 *Sst*⁺ cells: dIPAG: 84%; vIPAG: 99%). We also noticed that *Sst*⁺ cells were more abundant in the
118 vIPAG compared to the dIPAG (**Figure 2a-c**). Moreover, when considering *Sst* mRNAs expression
119 in inhibitory (*Slc32a1*⁺ or *Vgat* cells) or excitatory (*Slc17a6*⁺ or *Vglut2* cells) neurons, we observed
120 that the vast majority of dIPAG *Sst* mRNAs were expressed in excitatory neurons (91% of *Slc17a6*⁺
121 cells were *Sst*⁺ cells). In contrast, the vast majority of vIPAG *Sst* mRNAs were expressed in
122 inhibitory neurons (95% of *Slc32a1*⁺ cells were *Sst*⁺ cells; **Figure 2d-g**).

123 Next, to evaluate the contribution of vIPAG SST inhibitory neurons in FCA, SST-Cre mice were
124 injected in the vIPAG with a Cre-dependent AAV expressing the Channelrhodopsin (ChR2),
125 Archaelhodopsin (ArchT), or GFP and optic fiber were implanted above the area of interested and
126 submitted to the FCA task (**see Methods; Figure 3a, b**). Following conditioning, mice displayed
127 a significant increase in freezing behavior during CS⁺ compared to CS⁻ presentations or baseline
128 activity (**Figure 3c, e**). Moreover, the conditioning levels during retrieval were not different
129 between opsin and control groups (**Supplementary Figure 4a-d**). In the HP test following fear
130 retrieval, the optogenetic activation of SST cells in the vIPAG during CS⁻ had no effect, whereas
131 the same manipulation performed during CS⁺ blocked the analgesic effect compared to GFP
132 controls (**Figure 3d and Supplementary Figure 5a**). Conversely, optogenetic inhibition of vIPAG
133 SST cells promoted analgesia in both CS⁻ and CS⁺ conditions in comparison to GFP controls
134 (**Figure 3f and Supplementary Figure 5b**). Importantly, we controlled that the increased delay
135 and temperature at which mice displayed the nociceptive response during optogenetic manipulation
136 of vIPAG SST cells was not due to motor or aversive components by submitting SST-Cre mice to
137 optogenetic manipulation in an open field and a real-time place avoidance task (**Supplementary**
138 **Figure 5c-f**). Moreover, the optogenetic effect observed during FCA was not due to alteration of
139 somatostatin levels in our homozygous SST-Cre mice as we observed the same effect in
140 heterozygous SST-Cre mice (**Supplementary Figure 6a-d**). Finally, and in striking contrast with
141 vIPAG STT cells, the optogenetic inhibition of another important class of vIPAG inhibitory
142 neurons expressing the vasoactive intestinal peptide (VIP) did not change the analgesic levels
143 observed during CS⁻ or CS⁺ presentations (**Supplementary Figure 6e-h**). Together, these data
144 demonstrate that the selective inhibition of vIPAG SST cells promoted analgesia, whereas its
145 activation suppressed FCA during CS⁺ presentations.

147 **Activation of vIPAG SST cells reduced fear expression and promoted spinal cord-related**
148 **pain signals**

149 Because our novel FCA paradigm is dependent on fear associative processes (**Figure 1e-g and**
150 **Supplementary Figure 2**), it is possible that the optogenetic manipulation of vIPAG SST cells
151 may have altered the expression of aversive memories (i.e., freezing) and thereby the expression
152 of FCA. To control for this possibility, we optogenetically activated or inhibited vIPAG SST cells
153 during a fear retrieval session 24 hrs following auditory fear conditioning (**Figure 4a**). Our data
154 indicate that whereas the optogenetic inhibition of vIPAG SST cells had no effect on fear
155 expression relative to GFP controls, their optogenetic activation reduced fear expression (**Figure**
156 **4b-c**). Importantly, the optogenetic activation of vIPAG SST cells did not modify fear learning
157 when delivered concomitantly to the US (**Supplementary Figure 7**). These data clearly indicated
158 that the manipulation of vIPAG SST cells did not interfere with the acquisition of conditioned fear
159 behavior but that the activation of vIPAG SST cells impaired fear expression. These results have
160 significant consequences as they might represent a main confound for the reduction in FCA
161 observed during the optogenetic activation of vIPAG SST cells in the HP test during CS⁺
162 presentations (**Figure 3**). Indeed, the reduction of the response latency and temperature observed
163 in the HP test could have been due to a decrease in freezing behavior rather than a direct reduction
164 of FCA induced by vIPAG SST cells activation.

165 To control for this possibility, we reasoned that activation of vIPAG SST cells might reduce
166 FCA in the HP test by promoting nociception directly at the level of the spinal cord DH. Therefore,
167 we performed extracellular recording of the spinal cord network before, during, and after
168 optogenetic stimulation of vIPAG SST cells in mice under anesthesia to determine if nociceptive-
169 mediated field potentials were modified by the optogenetic activation or inhibition of vIPAG SST
170 cells (**Figure 5a**). Our results indicated that the optogenetic activation of vIPAG SST cells during

171 suprathreshold electrical stimulation of the paw potentiated, whereas their optogenetic inhibition
172 reduced, nociceptive field potentials (**Figure 5b, c**). To determine if this effect was specific for the
173 nociceptive network, we recorded wide dynamic range (WDR) neurons in the DH, known to
174 receive both tactile and nociceptive information. Suprathreshold C-fiber stimulations induced a fast
175 burst of spikes (0-80 ms), mediated by large-diameter myelinated non-nociceptive fibers, followed
176 by a slow burst of spikes (80-150 ms) mediated by low diameter unmyelinated nociceptive C-fiber
177 (**Figure 5a bottom**). Interestingly, the optogenetic activation of vIPAG SST cells increases both
178 responses, with a larger effect on nociceptive C-fibers (**Figure 5d**). Conversely, the optogenetic
179 inhibition of vIPAG SST cells specifically inhibited nociceptive responses while non-nociceptive
180 responses remained unaffected (**Figure 5e**). To confirm that vIPAG SST cells manipulation acts
181 predominantly on the nociceptive network, we performed two additional experiments. First, under
182 conditions in which subthreshold electrical stimulations failed to elicit WDR neuronal responses,
183 we observed that the optogenetic activation of vIPAG SST cells promoted WDR responses at a
184 latency corresponding to nociceptive fibers (**Figure 5f**). Second, we performed a windup protocol
185 inducing WDR short-term sensitization specific of nociceptive networks (**see Methods**). Our
186 results indicated that windup amplitude increased when vIPAG SST cells were activated and
187 decreased when vIPAG SST cells were inhibited compared to GFP controls (**Supplementary**
188 **Figure 8**). Consistent with our observation in freely moving mice in the HP test, these data strongly
189 suggest that activation and inhibition of vIPAG SST cells decreased and increased FCA by
190 specifically promoting nociception and antinociceptive responses in the spinal cord DH,
191 respectively.

192

193 **vIPAG SST cells mediating FCA contact RVM spinal cord-projecting neurons**

194 These data raise the question of whether vIPAG SST cells mediate their pronociceptive effect
195 by contacting directly WDR neurons in the spinal cord or alternatively by contacting center
196 structures projecting to the spinal cord. To address this question, we performed anatomical tracing
197 in mice injected in the vIPAG with a Cre-dependent AAV expressing GFP. Our analyses revealed
198 massive labeling of SST fibers in the rostral ventromedial medulla (RVM) (**Figure 6a, b**) and
199 sparse labeling within the spinal cord but not in the DH where nociceptive projections neurons are
200 present (data not shown). Importantly, in the same animals, fluorogold retrograde labeling of RVM
201 neurons projecting to the DH revealed close apposition of SST putative boutons and RVM neurons
202 projecting to the DH (**Figure 6d**), indicating that vIPAG SST cells project to the RVM and contact
203 DH-projecting RVM neurons. To address the function of these indirect vIPAG SST cells inputs to
204 the DH, we performed optogenetic activation of vIPAG SST inputs in the RVM (**Figure 6e**) while
205 recording from WDR neurons during electrical stimulation of the paw. Optogenetically activating
206 vIPAG SST inputs in the RVM resumed the WDR pain-response potentiation observed by
207 stimulating vIPAG SST compared to GFP controls (**Figure 6e-g and Supplementary Figure 9**).
208 Importantly, to exclude the contribution of potential “en passant” fibers projecting directly to the
209 spinal cord, we performed recordings of WDR neurons while directly optogenetically manipulating
210 descending fibers above the dorsal column. In contrast to direct vIPAG SST cells manipulation that
211 increased nociceptive response, the optogenetic manipulation of vIPAG SST inputs in the DH had
212 no effect on nociceptive transmission (**Figure 6h**). To further confirm in behaving animals that
213 activation of vIPAG SST neurons projecting to the RVM mediate FCA without interfering with
214 freezing behavior, SST cre mice were injected in the vIPAG with an AAV expressing ChR2 and
215 optic fibers placed above the RVM (**Figure 7a**). We first observed that activating vIPAG SST
216 neurons projecting to the RVM had no effect on fear expression (**Figure 7 b**) supporting the notion
217 that freezing behavior and FCA are mediated by distinct pool of vIPAG SST neurons. Next, another

218 cohort of AAV injected mice were fear conditioned and tested in the HP test. Following
219 conditioning, mice displayed a significant increase in freezing behavior during CS⁺ compared to
220 CS⁻ presentations or baseline activity (**Figure 7c**). In the HP test following fear retrieval, the
221 optogenetic activation of vIPAG SST terminals in the RVM during CS⁻ had no effect, whereas the
222 same manipulation performed during CS⁺ blocked the analgesic effect compared to GFP controls
223 (**Figure 7d**). Altogether, these data clearly demonstrate that vIPAG SST mediates FCA by
224 contacting RVM neurons projecting to the DH and suggest the existence of two populations of
225 vIPAG SST neurons mediating respectively FCA and freezing behavior.

226

227 **Discussion**

228 In this study, we demonstrated that inhibitory SST neurons located within the vIPAG are
229 causally involved in the regulation of pain responses during a threatful situation. First of all, our
230 data indicate that the development of FCA as shown with a reduction in thermal pain sensitivity
231 following cued fear conditioning depends on associative processes. Moreover, the use of a cue as
232 a conditioned stimulus instead of a context allows for a time-marked onset and offset. We argue
233 that using a cue makes the FCA model more suitable for time-controlled manipulations such as
234 optogenetics and electrophysiology recordings. To our knowledge, this is the first demonstration
235 of a conditioned analgesia paradigm using a cue as a CS instead of a context.

236 Second, our data indicate that the activation of vIPAG SST neurons impaired FCA, whereas
237 their inhibition increases analgesia in a CS-independent manner. Third, we observed that activation
238 and inhibition of vIPAG SST cells decreased and increased FCA by specifically promoting
239 pronociceptive and antinociceptive responses in the spinal cord DH. Finally, we demonstrated that
240 vIPAG SST mediates FCA by contacting RVM neurons projecting to the DH. Together these

241 results identify a novel brainstem circuit composed of vIPAG SST cells specifically projecting to
242 the RVM and mediating FCA to regulate pain responses during threatful situations.

243 Our observation that the optogenetic activation of vIPAG SST cells reduced FCA by promoting
244 pronociception at the spinal cord while simultaneously impacting freezing behavior opens
245 interesting questions. First, our results are in a contrast with the seminal study of Helmstetter and
246 Fanselow, who demonstrated that injection of the opioid antagonist naltrexone reversed
247 conditioned analgesia without impacting freezing behavior²⁰. Our data on vIPAG SST cells rather
248 suggest the existence of an overlap between the neuronal circuits mediating the expression of
249 freezing behavior and those involved in the regulation of pain processes. Indeed, a recent report
250 demonstrated that freezing expression critically depends on vIPAG disinhibitory mechanisms
251 involving local GABAergic interneurons⁹. This fear circuit recruits long-range inhibitory inputs
252 from the central medial amygdala contacting local inhibitory cells within the vIPAG, which
253 inhibition promoted the disinhibition of vIPAG excitatory neurons projecting to the motor center,
254 ultimately leading to freezing behavior. In this model, activating the local vIPAG inhibitory
255 neurons reduced fear expression, an observation similar to the effect we observed when we
256 optogenetically activated vIPAG SST cells (**Figure 4c**). This effect was accompanied in our case
257 with a reduction of FCA, which depends on the vIPAG SST projection to the RVM (**Figure 3d**).
258 Although these results may indicate that local vIPAG inhibitory neurons involved in freezing
259 expression correspond to vIPAG SST cells, our observation that the optogenetic inhibition of
260 vIPAG SST cells did not induce freezing behavior as observed in Tovote et al. suggests otherwise.
261 First of all, it is possible that different populations of SST neurons exhibiting local or distinct
262 remote connectivity co-exists within the vIPAG, which could explain why the optogenetic
263 manipulation in the vIPAG decreases both freezing expression and FCA. An alternative
264 explanation could be that other vIPAG interneuronal types are involved in freezing expression and

265 FCA. However, our optogenetic manipulation of another major class of vIPAG inhibitory cells
266 expressing VIP did not impact FCA (**Supplementary Figure 6e-h**). Additional vIPAG
267 microcircuits studies will be necessary to disentangle these issues.

268 Our data also indicate that the optogenetic activation of vIPAG SST cells reduced FCA during
269 CS⁺ presentations, whereas their inhibition was less specific and promoted FCA to both the CS⁻
270 and CS⁺ (**Figure 3**). Although we do not know whether vIPAG SST cells change their firing activity
271 during FCA, these data suggest that vIPAG SST cells activity is reduced during FCA and that
272 normalizing their activity using optogenetic activation is sufficient to prevent FCA. However, the
273 fact that optogenetically activating vIPAG SST cells during CS⁻ presentations has no effect on the
274 pain threshold indicates that vIPAG SST cells do not play a direct role in nociception mechanisms
275 when emotional systems are not engaged (i.e., during CS⁻ presentations) or alternatively is
276 indicative of a floor effect. Our data also suggest that inhibiting vIPAG SST cells activity promoted
277 analgesia even under conditions in which FCA is not induced (i.e., during CS⁻ presentations),
278 further supporting the idea that antinociception in the context of FCA is specifically mediated by a
279 reduction in the firing activity of vIPAG SST.

280 Our data also complement the classical lateral inhibition model of antinociception within the
281 PAG, relying on the activation of PAG excitatory neurons projecting to the RVM. More precisely,
282 in this model, analgesia is thought to occur through an opioid-dependent inhibition of GABAergic
283 neurons, ultimately disinhibiting excitatory neurons projecting to the RVM^{13,21}. This hypothesis
284 was recently confirmed by optogenetic experiments in which the optogenetic activation of PAG
285 glutamatergic neurons induced analgesia⁹. Our data indicate that in addition to this disinhibitory
286 mechanism, analgesia is also mediated by the inhibition of a direct long-range inhibitory projection
287 onto RVM neurons projecting to the DH (**Figure 6**). Thus, thermal analgesia relies on both
288 excitatory and inhibitory pathways projecting to the RVM. Further studies will be required to

289 identify which cells types are involved at the level of the RVM and whether other forms of
290 analgesia also rely on these excitatory and inhibitory inputs to the RVM. Finally, understanding
291 the circuits and mechanisms mediating FCA will extend our knowledge on the interplay between
292 emotional and pain systems.

293

294 **FIGURE LEGENDS**

295 **Figure 1. Emotional modulation of pain behavior. a.** Schematic of the setup and the FCA
296 paradigm. On Day 1, mice were habituated to the context and tones. On the conditioning day, one
297 of the tones (CS⁺) terminated with the onset of mild foot-shock (US) while the other tone remained
298 neutral (CS⁻). 24h later, the CS-US association was tested during the retrieval where both tones are
299 presented alone. Following retrieval, mice were submitted to the HP test. Each mouse underwent
300 two HP trials, one for each tone. The tones were presented while the temperature gradually
301 increased. The trial terminated once mice displayed a nociception response. **b.** During retrieval, the
302 average freezing values for CS⁺ was higher than CS⁻ or baseline (BL) periods (***, $P < 0.001$, one-
303 way repeated-measures ANOVA, $F = 160.861$, $n = 12$ mice). **c.** Time of nociceptive response on
304 the HP test during CS⁻ and CS⁺ trials. The emotional modulation of pain behavior led to an average
305 increase in the nociceptive time response by 22 s (**, $P < 0.01$, one-way repeated-measures
306 ANOVA, $F = 15.901$, $n = 12$ mice). **d.** For the extinction protocol, 24 CS⁺ were presented across
307 two separate extinction sessions. After the CS-US association was extinguished, mice were
308 submitted to the HP test. **e.** Mean freezing values throughout the extinction protocol. Mice acquired
309 the CS-US association (1st CS⁺ block vs BL/CS⁻ ***, $P < 0.001$, one-way repeated-measures
310 ANOVA, $F = 149.912$, $n = 10$ mice), followed by a rapid extinction (5th & 6th block of CS⁺ vs
311 BL/CS⁻ ns, $P > 0.05$, one-way repeated measured ANOVA, $F = 1.482$). **f.** After extinction, there

312 was no difference in the time of response between the two trials of the HP test (ns, $P > 0.05$, one-
313 way repeated-measures ANOVA, $F = 0.663$, $n = 10$ mice). **g.** Difference in the time of nociceptive
314 response between the CS^+ and CS^- trials for the extinction (Ext, $n = 10$ mice) and the control group
315 (normal FCA protocol; Ctr, $n = 12$ mice). The extinction group had a significantly lower difference
316 in time of nociceptive response than the control group (*, $P < 0.05$, One-way factorial ANOVA, F
317 $= 7.623$, $n = 21$ mice). Box-whisker plots indicate median, interquartile range, and 5th - 95th
318 percentiles of the distribution. Crosses indicate means. Bullets indicate individual mice values.

319 **Figure 2. Two distinct neuronal populations in SST- Cre mice within the PAG. a.**

320 Representative picture of single-molecular fluorescent in situ hybridization for *Sst* mRNAs in the
321 PAG. Scale bar, 400 μm . **b, c.** Single-molecular fluorescent in situ hybridization for *Sst* (green)
322 and Cre (red) mRNAs in the vIPAG (left). Histograms showing the co-expression of *Sst*/*Cre* as
323 percentage of *Sst*-expressing cells (green) and as percentage of Cre-expressing cells (red) in the
324 dIPAG and vIPAG (right). Scale bar, 20 μm . **d.** Single-molecular fluorescent in situ hybridization
325 for *Sst* (red) and *Slc32a1* (green) within the dIPAG (upper panel) and vIPAG (bottom panel). Scale
326 bar, 20 μm . **e.** Quantification of colocalization within the dIPAG (upper panel) and vIPAG (bottom
327 panel) of *Sst*⁺ and *Slc32a1*⁺. In the dIPAG approximately 19% of *Slc32a1*⁺ cells are *Sst*⁺ and 17%
328 of *Sst*⁺ cells are *Slc32a1*⁺. On the contrary, in the vIPAG approximately 95% of *Slc32a1*⁺ cells are
329 *Sst*⁺ and 61% of *Sst*⁺ cells are *Slc32a1*⁺. **f.** Single-molecular fluorescent in situ hybridization for *Sst*
330 (red) and *Slc17a6* (green) within the dIPAG (upper panel) and vIPAG (bottom panel). Scale bar,
331 20 μm . **g.** Quantification of colocalization within the dIPAG (upper panel) and vIPAG (bottom
332 panel) of *Sst*⁺ and *Slc17a6*⁺. In the dIPAG approximately 91% of *Slc17a6*⁺ cells are *Sst*⁺ and 38%
333 of *Sst*⁺ cells are *Slc17a6*⁺. On the contrary, in the vIPAG approximately 34% of *Slc17a6*⁺ cells are
334 *Sst*⁺ and 33% of *Sst*⁺ cells are *Slc17a6*⁺. White arrows indicate colocalization.

335 **Figure 3. SST⁺ neurons in vIPAG mediate the emotional modulation of pain behavior. a.** SST-
336 IRES-Cre mice received bilateral injection of opsins in the vIPAG, and optic fibers were implanted
337 above the region of interest. **b.** Representative example of expression patterns of ChR2 (left) and
338 ArchT (right) within SST⁺ vIPAG neurons. **c, e.** Average freezing values during retrieval for ChR2-
339 (c) and ArchT-infected mice (e) and their respective GFP-infected mice. The opsin and respective
340 control groups were pulled together because no difference was found in the conditioning level (see
341 **Supplementary Figure 4**). The average freezing values during CS⁺ was higher than CS⁻ or baseline
342 (BL) periods (***, $P < 0.001$, one-way repeated-measures ANOVA, (c) $F = 396.787$, $n = 16$ mice
343 and (e) $F = 280.420$, $n = 23$ mice). **d.** Light activation of SST⁺ neurons abolished the analgesic
344 effect of the fear modulation (*, $P < 0.05$, $n = 7$ GFP, $n = 9$ ChR2, opsin x CSs - two-way repeated-
345 measures ANOVA, $F_{(1,14)} = 8.514$). The nociception response time for the CS⁺ was significantly
346 different between the ChR2 and GFP group (**, $P = 0.0091$, unpaired t-test). For the ChR2 group,
347 the nociception response time during CS⁺ was equivalent to the CS⁻ (ns, $P = 0.4028$, ChR2,
348 unpaired t-test). On the contrary, the nociception response time between the CSs was different for
349 the GFP group (*, $P = 0.0157$, GFP, unpaired t-test). **f.** Light inhibition of SST⁺ neurons increased
350 the analgesic effect for the ArchT group when compared to the GFP (**, $P < 0.01$, $n = 12$ GFP, n
351 $= 11$ ArchT, opsin effect - two-way repeated measured ANOVA, $F_{(1,21)} = 20.548$, post hoc
352 Bonferroni $P = 0.0002$). There was also a significant effect for the interaction between the opsins
353 and the tones (**, $P < 0.01$, $n = 12$ GFP, $n = 11$ ArchT, opsin x CSs - two-way repeated measured
354 ANOVA, $F_{(1,21)} = 10.637$). The nociception response time for the CS⁻ and CS⁺ was significantly
355 different between the ArchT and GFP group (CS⁻: **, $P < 0.0001$, unpaired t-test; CS⁺:*, $P =$
356 0.0145 , unpaired t-test). For the GFP group, the time of nociception response was higher for the
357 CS⁺ trials when compared to the CS⁻ trials (**, $P = 0.0015$, GFP, unpaired t-test), yet this was not
358 the case for the ArchT group (ns, $P = 0.9561$, ArchT, unpaired t-test). Box-whisker plots indicate

359 median, interquartile range, and 5th - 95th percentiles of the distribution. Crosses indicate means.
360 Bullets indicate individual mice values.

361 **Figure 4. Modulation of SST⁺ vIPAG neurons is sufficient but not necessary to modulate**
362 **freezing. a.** Protocol for optogenetic manipulation during fear retrieval. Day 1 and 2 were done as
363 described previously for the FCA paradigm. During retrieval, there were 12 CS⁺ presentations
364 divided by three blocks. The optogenetic manipulation was done during the 2nd block of the CS⁺
365 presentation. **b.** Light inhibition of SST⁺ neurons in the vIPAG did not modulate freezing levels
366 (ns, $P = 0.0984$, $n = 6$, GFP 1st vs. 2nd CS⁺-block, unpaired t-test; ns, $P = 0.5979$, $n = 8$, ArchT 1st
367 vs. 2nd CS⁺-block, unpaired t-test). **c.** Light activation of the SST⁺ neurons in the vIPAG had no
368 effect on the GFP group (ns, $P = 0.1768$, $n = 9$, GFP 1st vs 2nd CS⁺-block, unpaired t-test) but it
369 transiently decreases the levels of freezing for the ChR2 group (***, $P = 0.001$, $n = 8$, ChR2 1st
370 vs. 2nd CS⁺-block, unpaired t-test). Box-whisker plots indicate median, interquartile range, and 5th
371 - 95th percentiles of the distribution. Crosses indicate means. Bullets indicate individual mice
372 values. Yellow and blue shaded rectangles represent the period of optical inhibition and activation,
373 respectively.

374 **Figure 5. Activation of vIPAG SST cells promotes spinal cord-related pain signals. a.**
375 Optogenetic manipulation of vIPAG SST cells with concomitant noxious electrical stimulation of
376 the paw in anesthetized mice while recording nociceptive field potentials in the lumbar spinal cord.
377 **b.** Representative trace of nociceptive field potentials in the lumbar spinal cord before and during
378 optogenetic activation of vIPAG SST cells (upper panel). The activation of vIPAG cells induces a
379 significant increase in the nociceptive fields (bottom panel; OFF₁ = 0.000095 ± 0.00001 $\mu\text{V}/\text{ms}$;
380 ON = 0.00017 ± 0.00002 $\mu\text{V}/\text{ms}$, OFF₂ = 0.000090 ± 0.00002 $\mu\text{V}/\text{ms}$; ***, $P < 0.001$, one-way
381 repeated-measures ANOVA, $F = 17.943$) **c.** Representative trace of nociceptive field potentials in

382 the lumbar spinal cord before and during optogenetic inhibition of vIPAG SST cells (upper panel).
383 The inhibition of vIPAG cells induces a significant decrease in the nociceptive fields (bottom panel;
384 $OFF_1 = 0.00017 \pm 0.00009 \mu\text{V}/\text{ms}$; $ON = 0.00006 \pm 0.00002 \mu\text{V}/\text{ms}$, $OFF_2 = 0.00012 \pm 0.00004$
385 $\mu\text{V}/\text{ms}$; $n = 6$. *, $P < 0.05$, Wilcoxon signed-rank test). **d.** Representative trace single-unit
386 recordings of WDR neurons before and during optogenetic activation of vIPAG SST neurons
387 (upper panel). The activation of vIPAG SST cells induces a significant and global increase in WDR
388 response to both C and A mediated peripheral fibers (bottom panel; *, $P < 0.05$, one-way repeated-
389 measures ANOVA, $F_{A\text{-fiber}} = 4.998$; ***, $P < 0.001$, one-way repeated-measures ANOVA, $F_{C\text{-fiber}} =$
390 22.966). **e.** Representative trace single-unit recordings of WDR neurons before and during
391 optogenetic inhibition of vIPAG SST neurons (upper panel). The inhibition of vIPAG SST cells
392 induces a significantly and, specifically, inhibition of WDR response to C-mediated peripheral
393 fibers (bottom panel; ***, $P < 0.001$, Wilcoxon signed-rank test). **f.** Representative traces of single-
394 unit recordings of WDR neurons with subthreshold electrical stimulation accompanied by
395 optogenetic activation of vIPAG SST neurons (upper panel). The optogenetic activation of vIPAG
396 SST cells elicits WDR response to C-mediated peripheral fibers (ns, $P = 0.1215$, A-fiber ON vs
397 OFF; ***, $P < 0.001$, C-fibers OFF vs ON - Wilcoxon signed-rank test).

398 **Figure 6. vIPAG SST cells mediating the FCA project to RVM cells.** **a.** Representative example
399 of expression patterns of GFP within SST^+ vIPAG neurons. **b.** A representative example of the
400 same mouse as in (a), GFP labelled fibers are present in the RVM (left panel). Higher magnification
401 reveals putative axonic buttons in the RVM (right panel; white arrows for putative axonic buttons).
402 **c.** SST Cre mice were injected concomitantly with GFP in the vIPAG and fluorogold in the lumbar
403 dorsal horn of the spinal cord. **d.** Fluorogold positive neurons (red) cross vIPAG SST fibers in the
404 RVM (green). Higher magnification shows close contacts between the putative SST^+ button and

405 fluorogold⁺ neurons or fibers (white arrows). **e.** Single-unit recordings of WDR neurons in the
406 lumbar spinal cord during optogenetic activation of vlPAG SST inputs to the RVM (left panel).
407 The optogenetic activation of vlPAG SST inputs to the RVM induces a significant increase in WDR
408 response to both C and A-mediated peripheral fibers stimulation (right panel; *, P < 0.05, A-fibers;
409 **, P < 0.01, C-fibers - Wilcoxon signed-rank test). **f.** Activation of vlPAG SST inputs to the RVM
410 switches a subliminal peripheral stimulation in a supraliminal response (OFF = 0.06 ± 0.04 spikes;
411 ON = 4.2 ± 1.2 spikes, n=10, **, P < 0.01, OFF vs. ON - Wilcoxon signed-rank test). **g.** Windup
412 coefficient of WDR cells is significantly increased by optogenetic activation of vlPAG SST inputs
413 to the RVM (OFF = 28 ± 18; ON = 78 ± 22, n=6, **, P < 0.01, OFF vs. ON - Wilcoxon signed-
414 rank test). **h.** Single-unit recordings of WDR neurons in the lumbar spinal cord during optogenetic
415 activation of vlPAG SST cells with optic fibers placed either above the vlPAG or above the lumbar
416 spinal cord (left panel). Light delivery above the vlPAG increased the WDR response to
417 nociceptive C-fiber stimulation but not if the light was delivered above the lumbar spinal cord
418 (right panel; ***, P < 0.001, vlPAG ON vs. OFF; ns, P = 0.2412, Spinal cord ON vs. OFF -
419 Wilcoxon signed-rank test).

420
421 **Figure 7. Modulation of SST⁺ vlPAG projecting to the RVM promoted FCA.** **a, top.** SST-
422 IRES-Cre mice received bilateral injection of an AAV expressing Chr2 or GFP in the vlPAG, and
423 optic fibers were implanted above the RVM. **Bottom,** Representative example of SST⁺ vlPAG
424 neurons terminals in the RVM. **b.** Light activation of vlPAG SST⁺ neurons projecting to the RVM
425 did not modulate freezing levels (ns, P = 0.0775, n = 7, GFP 1st vs. 2nd CS⁺-block, unpaired t-test;
426 ns, P = 0.0642, n = 6, Chr2 1st vs. 2nd CS⁺-block, unpaired t-test). **c.** Average freezing values
427 during retrieval for Chr2 and GFP-infected mice. The opsin and respective control groups were

428 pulled together because no difference was found in the conditioning level. The average freezing
429 values during CS⁺ was higher than CS⁻ or baseline (BL) periods (***, $P < 0.001$, one-way repeated-
430 measures ANOVA, (c) $F = 274.215$, $n = 14$ mice). **d.** Light activation of SST⁺ neurons abolished
431 the analgesic effect of the fear modulation (**, $P < 0.05$, $n = 7$ GFP, $n = 6$ ChR2, opsin x CSs -
432 two-way repeated-measures ANOVA, $F_{(1,12)} = 19.875$). For the ChR2 group, the nociception
433 response time during CS⁺ was equivalent to the CS⁻ (ns, ChR2, unpaired t-test $P = 6458$). On the
434 contrary, the nociception response time between the CSs was different for the GFP group (**, $P <$
435 0.01 , GFP, unpaired t-test).

436

437

438 **METHODS**

439 **Subject details**

440 We used either male C57BL6/J mice (Janvier), heterozygous or homozygous SST-IRES-Cre
441 mice (Jackson laboratory), or heterozygous VIP-IRES-Cre mice (Jackson Laboratory) age 8-14
442 weeks that were individually housed under a 12 h light-dark cycle and provided with food and
443 water ad libitum. All procedures were performed in accordance with standard ethical guidelines
444 (European Communities Directive 86/60-EEC) and were approved by the committee on Animal
445 Health and Care of Institut National de la Santé et de la Recherche Médicale and the French
446 Ministry of Agriculture and Forestry (agreement #A3312001).

447

448 **Behavioral apparatus**

449 *Fear conditioned analgesia task* was performed in three different contexts (**Figure 4a**). Context
450 A was used for *Habituation* and *Retrieval* and consisted of a plexiglass cylinder (25 x 24 cm

451 diameter) with a grey, smooth plastic floor, and house-lights. Context B was used for *Conditioning*
452 and consisted of a square plexiglass (25 x 40 cm) with a grid floor connected to a shocker
453 (Coulbourn Instruments) and brighter house-lights. A total of 5 scrambled foot-shocks of 1 s
454 duration and intensity of 0.8 mA were delivered via the grid floor and served as the unconditioned
455 stimulus (US). Context A and B were cleaned, respectively, with 70% ethanol or 1 % acetic acid
456 between different mice. Both contexts contained an infrared beams detection that automatically
457 scored freezing periods. Mice were considered freezing if no movement, except respiratory
458 movement, was detected for at least 2 s.

459 Context C was used for the *Hot Plate test* (HP test). A steady increase in temperature was
460 controlled by the Incremental Hot/Cold Plate Analgesia Meter (IITC) device. The device had a
461 testing surface enclosed in a square plexiglass surface (20.3 x 10 x 20.5 cm) to restrain the mice
462 movement. The mice's temperature and surroundings were recorded with an infrared digital
463 thermographic camera (Testo 885) placed ~ 50 cm above the testing surface. The thermal camera
464 had a spatial resolution of 320 × 240 pixels, a sampling rate of 25 Hz, and thermal sensitivity of
465 0.03 °C at 30 °C. The testing surface of context C was cleaned with water between different mice.
466 All three contexts were enclosed in an acoustic foam isolated box with speakers mounted on the
467 top of each compartment. The auditory conditioned stimulus (CS) consisting of either 7.5 kHz or
468 white-noise 50 ms pips at 1 Hz repeated 27 times, 2 ms rise and fall, 80 dB sound pressure level.

469 ***Open field task*** was performed in a square plexiglass arena (36 x 36 x 25cm). A LED mounted
470 on the top-right side of the arena signaled the start and end of different epochs for offline analyses.
471 A video camera recorded from above the arena at 30 fps for offline video-tracking purposes.

472 ***Real-Time Place Preference (RTPP) task*** was performed in a shuttlebox consisting of a
473 plexiglass box (40 x 10 x 30 cm) with a floor grid, where a small plastic hurdle (1 cm height)
474 divided the arena into two equal compartments while infrared beams detection automatically

475 monitored the mice shuttling between compartments (Imetronic). A video camera recorded from
476 above the arena at 30 fps for offline video-tracking purposes. For both the open field and RTPP
477 task, a free user video-tracking software (idTracker: Tracking individuals in a group by automatic
478 identification of unmarked animals) together with in-house codes in Matlab (The MathWorks, Inc.,
479 Natick, MA, USA) were used to analyze each condition.

480 **Behavioral paradigm**

481 ***Fear conditioned analgesia.*** WT Mice (n = 12) were habituated to the context and tones (Day
482 1). Four white-noise (CS⁻) and four 7.5 kHz (CS⁺) tones were presented sequentially and without
483 US reinforcement. In Conditioning (Day 2), five CS⁻ and five CS⁺ were presented in an
484 intermingled fashion. The CS⁺ presentations were paired with a mild foot-shock (US) at tone offset,
485 whereas the CS⁻ was never reinforced. The retrieval session (Day 3) was done 24h after
486 Conditioning and in the same context as the Habituation session. As in Habituation, four CS⁻ and
487 four CS⁺ were presented sequentially and without US reinforcement (**Figure 4a**).

488 Since the focus of this study was the emotional modulation of pain sensitivity, it was compulsory
489 to evaluate the associative fear levels before measuring its impact on pain sensitivity. Two indices
490 were computed: the discrimination index (DI), to assess the level of discrimination between CS⁻
491 and CS⁺, and the conditioning index (CI), which indicated the level of freezing to the tone
492 predicting the US. These indexes were calculated as follows: $DI = \frac{(Freezing\ to\ CS^+) - (Freezing\ to\ CS^-)}{(Freezing\ to\ CS^+) + (Freezing\ to\ CS^-)}$
493 and $CI = DI \times (Freezing\ to\ CS^+)$. Based on preliminary data, mice were only submitted to the HP
494 test if $DI \geq 0.4$ & $CI \geq 0.3$. Mice that did not fit the criteria were conditioned a second time. There
495 was a minimum time interval of 2 h between the retrieval and the HP test.

496 The HP test consisted of two trials, one trial where the CS⁺ was presented (HP_CS⁺) and another
497 where the CS⁻ was presented (HP_CS⁻). The two trials were counterbalanced within group. The

498 testing surface was set at 30 °C (**Supplementary Figure 1d**), and after a 60 s acclimatization
499 period, its temperature gradually increased at a rate of 6 °C per minute (HP start). Tone presentation
500 (CS⁺ or CS⁻) started 130 s after the HP start. Temperature increase and tone presentation terminated
501 concomitantly with the display of a nociception response. Valid nociception readout responses
502 included jumping or licking the hind-paw. The effect of the emotional modulation on pain
503 sensitivity was assessed by comparing the time (or temperature) of the nociceptive response
504 between the two HP trials: [$\Delta\text{HP} = (\text{HP_CS}^+) - (\text{HP_CS}^-)$]. There was a minimum of 30 min interval
505 between the two trials for each mouse, during which mice returned to their home cage.

506 Freezing levels during the HP test were manually scored offline. Three periods for the HP
507 freezing were defined: i. *baseline period*, 30 s before the CS onset; ii. *early period*, first 30 s of CS
508 presentation; iii. *late period*, 30 before CS offset (**Supplementary Figure 1d**). Freezing scoring
509 was calculated using the videos from the infrared digital thermographic camera. The nature of the
510 trial was blinded to the researcher.

511 **Extinction training.** On Day 3 and 4, mice (n =10) were submitted to an extinction training
512 protocol established by Courtin et al.⁷. Briefly, there were 4 CS⁻ and 12 CS⁺, presented in a non-
513 reinforced manner (**Figure 4d**). Mice were considered as having successfully extinguished the fear
514 expression if the level of freezing in the last 4 CS⁺ was not statistically different from the CS⁻. After
515 fear extinction, mice were submitted to the HP test, using the same parameters as in the FCA
516 paradigm.

517 **Stability training.** The first three days consisted of the classical FCA paradigm. On Day 4, mice
518 (n = 10) repeated the protocol applied on Day 3 (**Supplementary Figure 3a**). All mice that passed
519 the fear conditioning criteria (DI \geq 0.4 & CI \geq 0.3) on Day 3 were kept for the following day,
520 independent of their level of Conditioning on Day 4.

521 ***Vasoconstriction assay.*** To determine if vasoconstriction was a confound of the HP test
522 outcomes, we used a modified version of the FCA paradigm (**Supplementary Figure 3f**). During
523 the HP test (n = 13), the temperature was not gradually increased but maintained at 30 °C while
524 CSs were presented. The tones (CS⁺ or CS⁻) were presented for 120 s, and mice were kept for an
525 additional 50 s before the HP trial terminated. Offline, with the infrared videos, mice back and tail
526 were measured at 30 s intervals. For each measuring point, the temperature of three spots of the
527 two body part was averaged to create the body temperature for the back and tail for a given time
528 point and mouse.

529 ***Basal nociception assay.*** Naïve mice (n = 10) were submitted to the HP test (**Supplementary**
530 **Figure 2a, left panel**). Each mouse underwent two identical trials. The HP test was identical to the
531 one described in the FCA paradigm, except no tones were presented. There was a minimum of 30
532 min interval between the two trials, during which mice returned to a restful state on their home
533 cage.

534 ***Tone-specific nociception assay.*** Naïve mice (n = 12) were submitted to the HP test without
535 auditory fear conditioning (**Supplementary Figure 2a, middle panel**). Each animal underwent
536 two trials, one trial with a 7.5 kHz tone presentation and another with a WN tone presentation. The
537 tone presentation was counterbalanced. The HP test parameters were identical to the one described
538 for the FCA except that both tones were unconditioned.

539 ***Conditioning-specific nociception assay.*** Mice (n = 7) were submitted to the classical FCA
540 paradigm with one exception: on Day 3 during the HP test, no CSs were presented (**Supplementary**
541 **Figure 2a, right panel**). Mice were submitted to two identical HP trials.

542 ***Open Field assay.*** This test was used to determine the effect of optogenetic stimulation on
543 locomotion. Therefore, only mice from optogenetic experiments were submitted to this assay. Mice
544 could freely move during the entire test. The locomotion assay had a total duration of 9 min and

545 was divided into 3 min epochs. The first and third epochs were OFF periods in which no optical
546 stimulation occurred. During the second epoch, mice received optical stimulation (ON period). The
547 optogenetic stimulation effect was analyzed by comparing the overall distance traveled between
548 the OFF and ON epochs (**Supplementary Figure 5c, d**). Mice injected with GFP were used to test
549 the effect of heat and light of the stimulation itself.

550 ***Real-time Place Preference assay.*** During the entire duration of the assay, mice could freely
551 shuttle between the two compartments. Under a closed-loop stimulation, mice received photo-
552 stimulation upon entry in one of the two compartments. The stimulated compartment was
553 counterbalanced within the group. The optical stimulation effect was assessed by comparing the
554 time spent in the stimulated compartment between the ChR2 and GFP groups (**Supplementary**
555 **Figure 5f**).

556

557 **Virus injections and optogenetics**

558 For optogenetic manipulation of SST-Cre neurons in the vIPAG, 0.15-0.2 μ L of either ChR2
559 (AAV5-EF1a-DIO-hChR2(H134R)-EYFP, titer: 3.2×10^{12} - Vector Core, University of North
560 Carolina), ArchT (AAV9-CAG-FLEX-ArchT-GFP, titer: 4.7×10^{12} - Vector Core, University of
561 North Carolina) or GFP (AAV5-FLEX-GFP, titer: 4.5×10^{12} - Vector Core, University of North
562 Carolina) were bilaterally injected into the vIPAG of 8/9 weeks old SST-Cre mice from glass
563 pipettes (tip diameter 20-30 μ m) at the following coordinates relative to bregma: - 4.4 mm AP; \pm
564 1.5 mm ML; -2.45 mm DV from dura, with a 20 degrees angle. Injection coordinates for
565 manipulation of VIP-Cre neurons in the vIPAG were the following: - 4.4 mm AP; \pm 1.35 mm ML;
566 -2.5 mm DV from dura, with a 20 degrees angle.

567 At two weeks after the injections, mice were bilaterally implanted with custom-built optic fibers
568 (diameter: 200 μm ; numerical aperture: 0.39; Thorlabs) above the vIPAG at the following
569 coordinates relative to bregma: i) SST-IRES-Cre mice: - 4.4 mm AP; \pm 1.0 mm ML; -1.8 mm DV
570 from dura, with a 10 degrees angle; ii) VIP-IRES-Cre mice: - 4.4 mm AP; \pm 0.8 mm ML; -2.0 mm
571 DV from dura, with a 10 degrees angle. Mice for RVM manipulations were implanted at the
572 following coordinates relative to bregma: -5.8 mm AP; 0.0 mm ML; -5.2 DV from the dura. All
573 implants were secured using three stainless steel screws and Super-Bond cement (Sun Medical).
574 During surgery, long- and short-lasting analgesic agents were injected (Metacam, Boehringer;
575 Lurocaïne, Vetoquinol). After surgery, mice were allowed to recover for at least five days.
576 Afterward, mice were daily handled to familiarize themselves with being restrained for the
577 connection of the optic fibers. Behavioral experiments were performed at least four weeks after
578 viral injections. Only mice with correct placement of optic fibers and virus expression restricted to
579 vIPAG were included in the analyses.

580 For optogenetic excitation, light stimulation consisted of blue light (473 nm, \sim 8-10 mW at fiber
581 tip) delivered with 2 Hz frequency and 5 ms pulse duration. In contrast, optogenetic inhibition,
582 light stimulation consisted of green light (532 nm, \sim 8-10 mW at fiber tip) delivered continuously.
583 For optogenetic manipulations during the FCA paradigm of either vIPAG SST or VIP cells, the
584 light was delivered during the HP test and paired with the tone presentation.

585 For stimulation during the fear conditioning, two sets of experiments were performed in a
586 sequential manner. First, the foot-shock US was replaced by the optical stimulation. Then, the US
587 became the optical stimulation combined with the foot-shock (**Supplementary Figure 7a**). For
588 both conditions, the optogenetic stimulation started 5 s before and lasted until 5 s after CS⁺ offset.
589 The same mice were used for both experiments. For the manipulations during the fear retrieval,

590 there were 12 CS⁺ presentations divided into blocks of 4 CS⁺. The optogenetic stimulation was
591 paired with the second block of CS⁺.

592 **Fluorogold injection**

593 An incision between one to two cm was made slightly caudal to the peak of the dorsal hump to
594 expose the lumbar spinal region. The vertebra of interest was identified, and then a small incision
595 was made between the tendons and the vertebral column on either side. The vertebra was then
596 secured using spinal adaptor clamps, and all tissue was removed from the surface of the bone.
597 Pulled borosilicate glass capillaries (Ringcaps, disposable capillary pipettes with ring mark,
598 DURAN, Hirschmann Laborgeräte, Germany) was inserted in the space between 2 vertebrae and
599 allow to microinject 50 nL of fluorogold 2% in the dorsal horn of the spinal cord on both sides.

600 ***In vivo* electrophysiology**

601 Mice were anesthetized with isoflurane 4% for induction then 1.5% maintenance. The
602 experiment was started as soon as there was no longer any reflex. The colorectal temperature was
603 kept at 37 °C with a heating blanket. Two metal clamps were used to set the animal spine in a
604 stereotactic frame (M2E, France) for stability during electrophysiological recordings. Then, a
605 laminectomy was performed at T13-L1 to expose the lumbar part of the spinal cord. The dura mater
606 was carefully removed. A vaseline pool was formed around the exposed spinal segments to ensure
607 that no drug was administered beyond the area of interest. Custom-made optical fibers were placed
608 1mm above the dorsal spinal cord for optogenetic manipulations. C-fiber-evoked field potentials
609 were recorded in the deep lamina of the DH (at a depth range of 250 and 500 μm) with borosilicate
610 glass capillaries (2 MΩ, filled with NaCl 684 mM; Harvard Apparatus, Cambridge, MA, USA).
611 Field potentials were recorded with an ISODAM-amplifier (low filter: 0.1Hz to high filter: 0.1
612 kHz; World Precision Instruments, USA) in response to electrical stimulation of the ipsilateral paw.

613 Single unit recordings of WDR DH neurons were made with the same borosilicate glass capillaries
614 mentioned above and placed in the dorsal part of the spinal cord. The criterion for selecting a
615 neuron was the presence of an A-fiber-evoked response (0-80 ms) followed by a C-fiber-evoked
616 response (80-150 ms) to electrical stimulation of the ipsilateral sciatic nerve.

617 Trains (every 30 s) of electrical stimulation at two times the threshold for C-fibers were
618 performed before, during, and after optogenetic stimulations with an optic fiber placed above the
619 recording site. Subthreshold stimulations were performed below the threshold for C-fiber and A-
620 fiber, respectively. Windup was recorded by ten repetitive electrical stimulations at 1 Hz at two
621 times the C-fibers threshold.

622 **Histology analyses**

623 Mice were administered a lethal dose of Exagon and underwent transcardial perfusions via the
624 left ventricle with 4% w/v paraformaldehyde (PFA) in 0.1 M PB. Following dissection, brains were
625 post-fixed for 24 h at 4°C in 4% PFA. Brain sections of 80 µm-thick were cut on a vibratome,
626 mounted on gelatin-coated microscope slides, and dried. For verification of correct viral injections
627 and optic fiber location, serial 80 µm-thick slices containing the regions of interest were mounted
628 in VectaShield (Vector Laboratories) and were imaged using an epifluorescence system (Leica DM
629 5000) fitted with a 10-x dry objective. The location and the extent of the injections/infections were
630 visually controlled. Only infections targeting the vIPAG and optic fibers terminating, depending
631 on the experiment, above the vIPAG or RVM were included in the analyses. For a subset of
632 animals, verification of both viral expression in the vIPAG and location of optic fiber in RVM,
633 serial of 20 µm thin slices containing the RVM were incubated free-floating in 0.1 M PBS
634 containing Triton X-100 (0.3%), Bovine Serum Albumin (1%; Sigma-Aldrich), and chicken anti-
635 GFP antibody (1:1000; Avelabs) overnight at 4 °C. After washing in 0.1 M PBS, secondary

636 antibodies, Alexa fluor 488–conjugated goat anti-chicken (1:500), were added in 0.1-M PBS for 2
637 hours at room temperature. Sections were finally viewed on a confocal microscope (Leica TCS
638 SPE, Mannheim, Germany) fitted with a 20-x dry objective, and both 40-x and 63-x oil immersion
639 1.3 NA objective and confocal image stacks (0.75 μm steps) were acquired for each sample.

640 **Single molecular in situ hybridization**

641 Analyses of *Sst*, *Cre*, *Slc32a1* and *Slc17a6* mRNAs expression were performed using single
642 molecule fluorescent in situ hybridization (smFISH). Brains from 2 Sst-Cre male mice were rapidly
643 extracted and snap-frozen on dry ice and stored at -80°C until use. Fourteen μm coronal sections
644 of the PAG (bregma -4.60 mm) were collected directly onto Superfrost Plus slides (Fisherbrand).
645 RNAscope Fluorescent Multiplex labeling kit (ACDBio Cat No. 320850) was used to perform the
646 smFISH assay according to manufacturer's recommendations. Probes used for staining are Mm-
647 Sst (ACDBio Cat No. 404631), Mm-Slc32a1-C2 (ACDBio Cat No. 319191-C2), Mm-Slc17a6-C2
648 (ACDBio Cat No. 319171-C2), Cre (ACDBio Cat No. 312281) and Mm-Sst (ACDBio Cat No.
649 404631-C2). After incubation with fluorescent-labeled probes, slides were counterstained with
650 DAPI and mounted with ProLong Diamond Antifade mounting medium (Thermo Fisher scientific
651 P36961). Confocal microscopy and image analyses were carried out at the Montpellier RIO
652 imaging facility. Image covering the entire PAG was single confocal sections acquired using
653 sequential laser scanning confocal microscopy (Leica SP8) and stitched together as a single image.
654 Triple-labeled images from each region of interest (dPAG and vPAG) were single confocal sections
655 captured using sequential laser scanning confocal microscopy (Leica SP8). Values in the
656 histograms represent co-expression as percentage of *Sst*-expressing cells (green) and as percentage
657 of cells expressing the other markers tested (*Cre*, *Slc32a1* and *Slc17a6*) (3-4 images in the dPAG
658 and vPAG per mouse, $n = 2$ mice).

659 **Statistics**

660 All data are presented as means \pm s.e.m. Box-whisker plots indicate median, interquartile range,
661 and 5th - 95th percentiles of the distribution. Statistical analyses were performed with StatView
662 software. No statistical methods were used to predetermine sample sizes, but sample sizes were
663 based on our lab prior studies. No randomization was used to assign experimental groups. Blinding
664 for the opsin was done for optogenetics experiments. Animals used for the FCA paradigm not
665 satisfying the fear conditioning criteria after two conditioning sessions were discarded from the
666 study. Mice with an incorrect injection of the opsins or misplace location of the optic fibers were
667 discarded. No other mice or data points were excluded. Significance levels are indicated as follows:
668 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

669 For *in vivo* electrophysiology, field potentials were measured as the area above the curve in the
670 C-fiber range (80-300 ms). Absolute values were used to compare values in each condition (OFF
671 vs. ON optogenetic manipulation). In single-unit recordings, the number of A- and C-fiber induced
672 spikes of WDR neurons were measured after each electrical stimulation, during and after
673 optogenetic manipulation. An average of the four stimulations for each WDR recorded was used
674 for statistical analysis. For windup measurement, a series of 10 repetitive electrical stimulations at
675 1 Hz and two times over the threshold for C-fibers were performed. A windup coefficient was
676 measured as the sum of C-spikes of the ten different stimulations subtracted ten times the response
677 to the first stimulation (Sum (R1+R2+...+R10)-10*(R1)). A Wilcoxon matched-pairs signed-rank
678 test was performed to compare the response before and during optogenetic manipulation.

679

680

681 **REFERENCES**

682

- 683 1 Fanselow, M. S. & Helmstetter, F. J. Conditional analgesia, defensive freezing, and
684 benzodiazepines. *Behavioral neuroscience* **102**, 233-243, doi:10.1037//0735-
685 7044.102.2.233 (1988).
- 686 2 Butler, R. K. & Finn, D. P. Stress-induced analgesia. *Progress in neurobiology* **88**, 184-
687 202, doi:10.1016/j.pneurobio.2009.04.003 (2009).
- 688 3 Jennings, E. M., Okine, B. N., Roche, M. & Finn, D. P. Stress-induced hyperalgesia.
689 *Progress in neurobiology* **121**, 1-18, doi:10.1016/j.pneurobio.2014.06.003 (2014).
- 690 4 Olango, W. M. & Finn, D. P. Neurobiology of stress-induced hyperalgesia. *Current topics*
691 *in behavioral neurosciences* **20**, 251-280, doi:10.1007/7854_2014_302 (2014).
- 692 5 McWilliams, L. A., Cox, B. J. & Enns, M. W. Mood and anxiety disorders associated with
693 chronic pain: an examination in a nationally representative sample. *Pain* **106**, 127-133,
694 doi:10.1016/s0304-3959(03)00301-4 (2003).
- 695 6 Basbaum, A. I. & Fields, H. L. Endogenous pain control systems: brainstem spinal
696 pathways and endorphin circuitry. *Annu Rev Neurosci* **7**, 309-338,
697 doi:10.1146/annurev.ne.07.030184.001521 (1984).
- 698 7 Courtin, J., Chaudun, F., Rozeske, R. R., Karalis, N., Gonzalez-Campo, C., Wurtz, H.,
699 Abdi, A., Baufreton, J., Biennu, T. C. & Herry, C. Prefrontal parvalbumin interneurons
700 shape neuronal activity to drive fear expression. *Nature* **505**, 92-96,
701 doi:10.1038/nature12755 (2014).
- 702 8 Samineni, V. K., Grajales-Reyes, J. G., Copits, B. A., O'Brien, D. E., Trigg, S. L., Gomez,
703 A. M., Bruchas, M. R. & Gereau, R. W. t. Divergent Modulation of Nociception by
704 Glutamatergic and GABAergic Neuronal Subpopulations in the Periaqueductal Gray.
705 *eNeuro* **4**, doi:10.1523/ENEURO.0129-16.2017 (2017).
- 706 9 Tovote, P., Esposito, M. S., Botta, P., Chaudun, F., Fadok, J. P., Markovic, M., Wolff, S.
707 B., Ramakrishnan, C., Fenno, L., Deisseroth, K., Herry, C., Arber, S. & Luthi, A. Midbrain
708 circuits for defensive behaviour. *Nature* **534**, 206-212, doi:10.1038/nature17996 (2016).
- 709 10 Floyd, N. S., Price, J. L., Ferry, A. T., Keay, K. A. & Bandler, R. Orbitomedial prefrontal
710 cortical projections to distinct longitudinal columns of the periaqueductal gray in the rat.
711 *The Journal of comparative neurology* **422**, 556-578 (2000).
- 712 11 LeDoux, J. E., Iwata, J., Cicchetti, P. & Reis, D. J. Different projections of the central
713 amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. *The*
714 *Journal of neuroscience : the official journal of the Society for Neuroscience* **8**, 2517-2529
715 (1988).
- 716 12 Vertes, R. P. Differential projections of the infralimbic and prelimbic cortex in the rat.
717 *Synapse* **51**, 32-58, doi:10.1002/syn.10279 (2004).
- 718 13 Fields, H. State-dependent opioid control of pain. *Nature reviews. Neuroscience* **5**, 565-
719 575, doi:10.1038/nrn1431 (2004).
- 720 14 Harris, J. A. Descending antinociceptive mechanisms in the brainstem: their role in the
721 animal's defensive system. *Journal of physiology, Paris* **90**, 15-25 (1996).
- 722 15 Reynolds, D. V. Surgery in the rat during electrical analgesia induced by focal brain
723 stimulation. *Science* **164**, 444-445 (1969).
- 724 16 Castilho, V. M., Macedo, C. E. & Brandao, M. L. Role of benzodiazepine and serotonergic
725 mechanisms in conditioned freezing and antinociception using electrical stimulation of the
726 dorsal periaqueductal gray as unconditioned stimulus in rats. *Psychopharmacology* **165**,
727 77-85, doi:10.1007/s00213-002-1246-4 (2002).

- 728 17 Vianna, D. M. & Carrive, P. Changes in cutaneous and body temperature during and after
729 conditioned fear to context in the rat. *The European journal of neuroscience* **21**, 2505-2512,
730 doi:10.1111/j.1460-9568.2005.04073.x (2005).
- 731 18 Lau, B. K. & Vaughan, C. W. Descending modulation of pain: the GABA disinhibition
732 hypothesis of analgesia. *Current opinion in neurobiology* **29**, 159-164,
733 doi:10.1016/j.conb.2014.07.010 (2014).
- 734 19 Lein, E. S., Hawrylycz, M. J., Ao, N., Ayres, M., Bensinger, A., Bernard, A., Boe, A. F.,
735 Boguski, M. S., Brockway, K. S., Byrnes, E. J., Chen, L., Chen, L., Chen, T. M., Chin, M.
736 C., Chong, J., Crook, B. E., Czaplinska, A., Dang, C. N., Datta, S., Dee, N. R., Desaki, A.
737 L., Desta, T., Diep, E., Dolbeare, T. A., Donelan, M. J., Dong, H. W., Dougherty, J. G.,
738 Duncan, B. J., Ebbert, A. J., Eichele, G., Estin, L. K., Faber, C., Facer, B. A., Fields, R.,
739 Fischer, S. R., Fliss, T. P., Frensley, C., Gates, S. N., Glattfelder, K. J., Halverson, K. R.,
740 Hart, M. R., Hohmann, J. G., Howell, M. P., Jeung, D. P., Johnson, R. A., Karr, P. T.,
741 Kawal, R., Kidney, J. M., Knapik, R. H., Kuan, C. L., Lake, J. H., Laramee, A. R., Larsen,
742 K. D., Lau, C., Lemon, T. A., Liang, A. J., Liu, Y., Luong, L. T., Michaels, J., Morgan, J.
743 J., Morgan, R. J., Mortrud, M. T., Mosqueda, N. F., Ng, L. L., Ng, R., Orta, G. J., Overly,
744 C. C., Pak, T. H., Parry, S. E., Pathak, S. D., Pearson, O. C., Puchalski, R. B., Riley, Z. L.,
745 Rockett, H. R., Rowland, S. A., Royall, J. J., Ruiz, M. J., Sarno, N. R., Schaffnit, K.,
746 Shapovalova, N. V., Sivasay, T., Slaughterbeck, C. R., Smith, S. C., Smith, K. A., Smith,
747 B. I., Sodt, A. J., Stewart, N. N., Stumpf, K. R., Sunkin, S. M., Sutram, M., Tam, A.,
748 Teemer, C. D., Thaller, C., Thompson, C. L., Varnam, L. R., Visel, A., Whitlock, R. M.,
749 Wohnoutka, P. E., Wolkey, C. K., Wong, V. Y., Wood, M., Yaylaoglu, M. B., Young, R.
750 C., Youngstrom, B. L., Yuan, X. F., Zhang, B., Zwingman, T. A. & Jones, A. R. Genome-
751 wide atlas of gene expression in the adult mouse brain. *Nature* **445**, 168-176,
752 doi:10.1038/nature05453 (2007).
- 753 20 Helmstetter, F. J. & Fanselow, M. S. Effects of naltrexone on learning and performance of
754 conditional fear-induced freezing and opioid analgesia. *Physiol Behav* **39**, 501-505,
755 doi:10.1016/0031-9384(87)90380-5 (1987).
- 756 21 Moreau, J. L. & Fields, H. L. Evidence for GABA involvement in midbrain control of
757 medullary neurons that modulate nociceptive transmission. *Brain research* **397**, 37-46,
758 doi:10.1016/0006-8993(86)91367-3 (1986).

759

760 **ACKNOWLEDGMENTS**

761 We thank the Herry team for fruitful discussions and careful reading of the manuscript; K.
762 Deisseroth and E. Boyden for generously sharing material, S. Laumond, J. Tessaire and the
763 technical staff of the housing and experimental animal facility of the Neurocentre Magendie.
764 Microscopy was performed in the Bordeaux Imaging Center of the CNRS-INSERM and Bordeaux
765 University, member of France BioImaging. This work was supported by grants from the French
766 National Research Agency (ANR-FEARLESSPAIN, ANR-DOPAFEAR, ANR-10-EQPX-08

767 OPTOPATH) and the Fondation pour la Recherche Médicale (FRM-PhD grant to NW 2020-2021).

768

769 **AUTHOR CONTRIBUTIONS**

770 N.W and S.V performed behavioral experiments. N.W and D.J performed optogenetic experiments
771 on freely moving animals. F.A performed electrophysiological and optogenetic experiments on
772 anesthetized animals. L.C, E.V, N.W, F.A, D.J and GZ performed histology. N.W, M.L, S.V. P.F
773 and C.H. designed the experiments. N.W, F.A, D.J and E.V analysed the data, N.W, P.F and C.H
774 wrote the paper.

775

776 **SUPPLEMENTARY FIGURES**

777 **Supplementary Figure 1: Fear-conditioned analgesia behavior.** **a.** During habituation, the
778 freezing levels for the context (BL) and the two tones were low but significantly different (***, P
779 < 0.001 , one-way repeated-measures ANOVA, $F = 15.562$, $n = 12$). **b.** Conditioning curves for CS^+
780 and CS^- . Overall, average freezing levels for BL was different when compared to the CS s (***, P
781 < 0.001 , one-way repeated-measures ANOVA, $F = 9.273$, $n = 12$). Freezing levels for the last tone
782 presentation during conditioning was not significantly different between CS^+ and CS^- (ns, $P =$
783 0.7805 , one-way repeated-measures ANOVA, $F = 0.082$, $n = 12$) **c.** -Temperature at which a
784 nociceptive behavioral response was observed in the HP. The temperature of nociception response
785 was higher during CS^+ trials when compared to the CS^- trials (**, $P < 0.01$, one-way repeated
786 measures ANOVA, $F = 20.067$, $n = 12$). **d.** Schematics of the HP kinetics. Mice had 1 min to
787 acclimatize to the context. Then the temperature steadily increase at 6 °C per min (HP start). The
788 CS s started 130 s after the HP start and continued until mice displayed a nociception response

789 (licking the hind-paw or jumping). At this point, both the CS and the temperature increase stopped,
790 ending the trial. Offline, 3 points were determined: i. *Baseline*, 30 s before CS onset; ii. *Early*, first
791 30 s of the CS; iii. *Late*, last 30 s of the CS offset. In purple, an exemplary trace of a trial recorded
792 with the infrared digital thermographic camera. **e.** Freezing levels during the HP test for CS⁻ and
793 CS⁺ presentation. Freezing levels were measured offline during *baseline*, *early* and *late* periods
794 (see Methods). Freezing was significantly higher during the CS⁺ presentation but only during the
795 early period (***, $P < 0.001$, one-way repeated measures ANOVA, $F = 94.753$, $n = 12$). Box-
796 whisker plots indicate median, interquartile range, and 5th - 95th percentiles of the distribution.
797 Crosses indicate means. Bullets indicate individual mice values.

798 **Supplementary Figure 2: FCA depends on associative processes. a, Left**, protocol for the basal
799 nociceptive assay: mice were submitted to two HP trials without conditioning nor tone presentation.
800 **Center**, protocol for the tone-specific assay: mice were submitted to two HP trials paired with tone
801 presentation (7.5 kHz or WN). **Right**, protocol for the conditioning-specific assay: mice were
802 submitted to auditory fear conditioning. However, during the HP test, no CSs were presented. **b.**
803 Mice submitted to auditory fear conditioning. During retrieval, the average freezing values for CS⁺
804 was higher compared to CS⁻ or baseline (BL) periods (***, $P < 0.001$, one-way repeated-measures
805 ANOVA, $F = 228.840$, $n = 7$ mice). **c, d.** Time and temperature of nociception response for all the
806 tests mentioned above. Fear conditioning induced analgesia compared to the basal nociception and
807 the tone-specific assay (Response latency: ***, $P < 0.001$, two-way repeated measures ANOVA,
808 type of assay $F_{(2,26)} = 11.567$, post hoc Bonferroni $P_{FC \text{ vs basal nociception}} < 0.001$ and $P_{FC \text{ vs tone assay}} =$
809 0.0013 ; Temperature : **, $P < 0.01$, two-way repeated measures ANOVA, type of assay $F_{(2,26)} =$
810 8.510 post hoc Bonferroni $P_{FC \text{ vs basal nociception}} = 0.0004$ and $P_{FC \text{ vs tone assay}} = 0.007$). Trials between
811 the same type of test were not significantly different (Response latency: ns, $P > 0.05$, two-way

812 repeated measures ANOVA, trial effect $F_{(1,26)} = 0.380$; Temperature: ns, $P > 0.05$, two-way repeated
813 measures ANOVA, trial effect $F_{(1,26)} = 0.093$). Box-whisker plots indicate median, interquartile
814 range and 5th - 95th percentiles of the distribution. Crosses indicate means. Bullets indicate
815 individual mice values. **e**, After fear extinction, there was no difference in temperature response
816 between the two CSs (ns, $P > 0.05$, one-way repeated measures ANOVA, $F = 1.071$, $n = 10$ mice).

817 **Supplementary Figure 3: The FCA paradigm is stable and is not mediated by changes in**
818 **body temperature. a.** Protocol for stability training (see methods). Mice were submitted to two
819 rounds of the FCA paradigm. During retrieval (**b**, **c**), average freezing values during CS⁺ was higher
820 than CS⁻ or baseline (BL) periods (***, $P < 0.001$, one-way repeated-measures ANOVA, $F_{\text{retrieval1}}$
821 (**b**) = 558.250 / $F_{\text{retrieval2}}$ (**c**) = 55.997, $n = 10$ mice). No differences were observed between the
822 freezing levels of retrieval 1 (**b**) and retrieval 2 (**c**) (ns, $P > 0.05$, two-way repeated-measures
823 ANOVA, $F_{(1,9)} = 4.078$, $n = 10$ mice). **d**, **e**. Time of nociception response during CS⁻ and CS⁺ trials.
824 The emotional modulation of pain behaviour increased the time of nociception response in HP1 (**d**,
825 Response latency : **, $P < 0.01$, one-way repeated-measures ANOVA, $F = 16.435$, $n = 10$ mice;
826 Temperature: **, $P < 0.01$, one-way repeated-measures ANOVA, $F = 26.876$, $n = 10$ mice) and in
827 HP2 (**e**, Response latency : *, $P < 0.05$, one-way repeated-measures ANOVA, $F = 6.046$, $n = 10$
828 mice; Temperature: *, $P < 0.05$, one-way repeated-measures ANOVA, $F = 7.272$, $n = 10$ mice).
829 No differences were found in the pain responses between the two tests (Response latency: ns, $P >$
830 0.05 , test effect, two-way repeated-measures ANOVA, $F_{(1,9)} = 0.134$, $n = 10$ mice; Temperature:
831 ns, $P > 0.05$, test effect, two-way repeated-measures ANOVA, $F_{(1,9)} = 0.160$, $n = 10$ mice). **f**.
832 Schematic representation of the protocol used (**top**). After fear conditioning, mice were submitted
833 to the HP test in which the temperature of the testing surface was kept at 30 °C for the entire
834 duration of the test. The CSs were introduced at 130 s and were played for 120 s. Mice were kept

835 in the HP device for another 60 s. The temperature of the mice back and tail were measured by the
836 infrared digital thermographic camera (**bottom**) and analysed offline (see Methods). The average
837 temperature of the mice back (**g**) and tail (**h**) while the CS⁺ or the CS⁻ were presented. There were no
838 differences on body temperature for the different CSs trials (ns, $P > 0.05$, two-way repeated-
839 measures ANOVA, $F_{(1,11)} \text{ back} = 0.328 / F_{(1,11)} \text{ tail} = 0.191$, $n = 13$ mice). Dashed lines correspond
840 to the average time of nociception response for the CS⁺ (red) and CS⁻ (blue) during the standard
841 FCA protocol. Box-whisker plots indicate median, interquartile range, and 5th - 95th percentiles
842 of the distribution. Crosses indicate means. Bullets indicate individual mice values.

843 **Supplementary Figure 4: Comparable fear levels prior to the HP test.** After retrieval, fear
844 conditioning levels between the opsins and their respective GFP group was tested to ensure
845 equivalent fear levels. The discrimination index (see methods) between the GFP and ChR2 (**a**, ns,
846 $P > 0.05$, one-way factorial ANOVA, $F = 0.280$, $n = 16$ mice) or ArchT (**b**, ns, $P > 0.05$, one-way
847 factorial ANOVA, $F = 0.573$, $n = 23$ mice) were not significantly different. All the mice
848 discriminated equally between CSs. The conditioning index (see methods) between the GFP and
849 ChR2 (**c**, ns, $P > 0.05$, one-way factorial ANOVA, $F = 1.553$, $n = 16$ mice) or ArchT (**d**, ns, $P >$
850 0.05 , one-way factorial ANOVA, $F = 2.455$, $n = 23$ mice) were also not significantly different. All
851 mice displayed a similar high freezing level to the CS⁺. Box-whisker plots indicate median,
852 interquartile range, and 5th - 95th percentiles of the distribution. Crosses indicate means. Bullets
853 indicate individual mice values.

854 **Supplementary Figure 5: Optogenetic controls for SST vIPAG neurons mediating FCA. a.**
855 Optogenetic activation of SST⁺ neurons abolished the analgesic effect induced during exposure to
856 the CS⁺ (*, $P < 0.05$, $n = 7$ GFP, $n = 9$ ChR2, opsin x CSs - two-way repeated-measures ANOVA,
857 $F_{(1,14)} = 11.400$). The temperature of the nociception response for the CS⁺ was significantly different

858 between the Chr2 and GFP group (**, $P = 0.0081$, unpaired t-test). For the Chr2 group, the
859 temperature of nociception response during CS^+ was equivalent to the CS^- (ns, $P = 0.3459$, Chr2,
860 unpaired t-test). On the contrary, the temperature of the nociception response between the CSs was
861 different for the GFP group (*, $P = 0.0108$, GFP, unpaired t-test). **b.** Optogenetic inhibition of SST^+
862 neurons augmented the analgesic effect for the ArchT group when compared to the GFP (**, $P <$
863 0.01 , $n = 12$ GFP, $n = 11$ ArchT, opsin effect - two-way repeated-measures ANOVA, $F_{(1,21)} =$
864 18.020 , post hoc Bonferroni $P = 0.0042$). The effect was also significant for the interaction between
865 the opsins and the tones (**, $P < 0.01$, $n = 12$ GFP, $n = 11$ ArchT, opsin x CSs - two-way repeated-
866 measures ANOVA, $F_{(1,21)} = 10.841$). The nociception temperature response for the CS^- and CS^+
867 was significantly different between the ArchT and GFP group (CS^- : **, $P < 0.0001$, unpaired t-test;
868 CS^+ : *, $P = 0.0472$, unpaired t-test). For the GFP group, the temperature of nociception response
869 was higher for the CS^+ trials when compared to the CS^- trials (**, GFP, unpaired t-test $P = 0.0014$),
870 yet this was not the case for the ArchT group (ns, ArchT, unpaired t-test $P = 0.9288$). **c.** Optogenetic
871 excitation of SST^+ vIPAG neurons was performed during the ON epoch (blue shaded area), and the
872 average distance travelled was not different from the OFF epochs when comparing the two opsins
873 (ns, $P > 0.05$, $n = 7$ GFP, $n = 9$ Chr2, opsin x distance - two-way repeated-measures ANOVA,
874 $F_{(2,28)} = 0.685$). **b.** Optogenetic inhibition of SST^+ vIPAG neurons was performed during the ON
875 epoch (yellow shaded area) and the average distance travelled was not different from the OFF
876 epochs when comparing the two opsins (ns, $P > 0.05$, $n = 12$ GFP, $n = 11$ ArchT, opsin x distance
877 - two-way repeated measures ANOVA, $F_{(2,42)} = 0.924$). **e.** Real-time place-preference location plot
878 from a representative animal while submitted to optogenetic activation of SST vIPAG neurons in
879 the left compartment throughout the 15-min session. **f.** There was no difference between Chr2-
880 expressing mice and the control group in the time spent on the stimulated compartment (ns,
881 unpaired t-test $P = 0.19$). Box-whisker plots indicate median, interquartile range and 5th - 95th

882 percentiles of the distribution. Crosses indicate means. Bullet points indicate individual mice
883 values.

884 **Supplementary Figure 6: Optogenetic effect observed during FCA is not due to alteration of**
885 **somatostatin levels nor mediated by VIP vIPAG neurons. a.** SST-IRES-Cre heterozygotic mice
886 received a bilateral injection of opsins in the vIPAG, and optic fibers were implanted above the
887 region of interest. **b.** A representative example of expression patterns of ChR2 within SST⁺ vIPAG
888 neurons. **c.** Average freezing values during retrieval. The ChR2 and GFP group were pulled
889 together because no differences were found in the conditioning level (data not shown). The average
890 freezing values during CS⁺ was higher than CS⁻ or baseline (BL) periods (***, $P < 0.0001$, one-
891 way repeated-measures ANOVA, $F = 293.847$, $n = 13$ mice). **d.** Optogenetic activation of SST⁺
892 heterozygotic neurons abolished the analgesic effect of the fear modulation (**, $P < 0.01$, $n = 6$
893 GFP, $n = 7$ ChR2, opsin x CSs - two-way repeated-measures ANOVA, $F_{(1,11)} = 12.390$). The
894 temperature of the nociception response for the CS⁺ was significantly different between the ChR2
895 and GFP group (*, $P = 0.0200$, unpaired t-test). For the ChR2 group, the latency of nociception
896 response during CS⁺ was equivalent to the CS⁻ (ns, ChR2, unpaired t-test $P = 0.4419$). On the
897 contrary, the latency of nociception response between the CSs was different for the GFP group (**,
898 GFP, unpaired t-test $P = 0.0011$). **e.** VIP-IRES-Cre mice received a bilateral injection of opsins in
899 the vIPAG, and optic fibers were implanted above the region of interest. **f.** Representative example
900 of the expression pattern of ArchT within VIP⁺ vIPAG neurons. **g.** The ArchT and GFP groups
901 were pulled together because no differences were found in the conditioning level (data not shown).
902 The average freezing values during CS⁺ was higher than CS⁻ or baseline (BL) periods (***, $P <$
903 0.0001 , one-way repeated-measures ANOVA, $F = 147.078$, $n = 10$ mice). **h.** Optogenetic inhibition
904 of VIP⁺ neurons did not change the analgesic effect for the ArchT group when compared to the

905 GFP (ns, $P > 0.05$, $n = 5$ GFP, $n = 5$ ArchT, opsin effect - two-way repeated measure ANOVA,
906 $F_{(1,8)} = 1.527$). The effect was also not significant for the interaction between opsins and tones (ns,
907 $P > 0.05$, $n = 5$ GFP, $n = 5$ ArchT, opsin x CSs - two-way repeated measured ANOVA, $F_{(1,8)} =$
908 0.398). The latency of nociception response was higher for the CS⁺ trials when compared to the
909 CS⁻ trials (**, unpaired t-test $P_{\text{GFP}} = 0.002 / P_{\text{ArchT}} = 0.0002$). Scale bars, 0.5 mm Box-whisker plots
910 indicate median, interquartile range, and 5th - 95th percentiles of the distribution. Crosses indicate
911 means. Bullet points indicate individual mice values.


912 **Supplementary Figure 7: SST vIPAG neurons do not modulate the CS-US association. a.**

913 Protocol for optogenetic manipulations during fear conditioning. On Day 2, mice received 5 CS-
914 US associations. The US was either optogenetic stimulation alone or optogenetic stimulation plus
915 foot-shock. **b.** Average freezing curve during the CS-US association of optogenetic stimulation
916 alone. There was no difference in the overall freezing levels for the CS⁻ and CS⁺ between Chr2
917 and GFP (ns, $P > 0.05$, optogenetic stimulation effect - two-way repeated-measures ANOVA, $F_{(1,11)}$
918 $= 0.983$, $n = 13$ mice). **c.** During retrieval, average freezing values for CS⁺ was not significantly
919 different from CS⁻ periods (ns, $P > 0.05$, CSs effect - two-way repeated-measures ANOVA, $F_{(1,11)}$
920 $= 0.095$, $n = 13$ mice). There was no effect on fear expression upon activation of SST⁺ vIPAG
921 neurons as an US (ns, $P > 0.05$, CSs x opsin effect - two-way repeated-measures ANOVA, $F_{(1,11)} =$
922 3.020 , $n = 13$ mice). **d.** Average freezing curve during the CS-US association of optogenetic
923 stimulation plus foot-shock. There was no difference in the overall freezing levels for the CS⁺ and
924 CS⁻ between Chr2 and GFP (ns, $P > 0.05$, optogenetic stimulation effect - two-way repeated-
925 measures ANOVA, $F_{(1,11)} = 0.9575$, $n = 13$ mice). **e.** During retrieval, the average freezing values
926 during CS⁺ was higher than CS⁻ or baseline (BL) periods for both GFP and Chr2 (***, $P < 0.001$,
927 one-way repeated-measures ANOVA, $F_{\text{GFP}} = 146.847$, $n = 6$ mice / $F_{\text{Chr2}} = 40.793$, $n = 7$ mice).


928 However, there was no difference of the fear expression by the activation of the SST⁺ vIPAG
929 neurons (ns, $P > 0.05$, CSs x opsin effect - two-way repeated-measures ANOVA, $F_{(1,11)} = 0.110$;
930 (ns, $P > 0.05$, CSs x opsin effect - two-way repeated-measures ANOVA, $F_{(1,11)} = 0.110$, $n = 13$
931 mice). Box-whisker plots indicate median, interquartile range, and 5th - 95th percentiles of the
932 distribution. Crosses indicate means. Grey bullet points indicate individual mice values.

933
934 **Supplementary Figure 8: Windup protocol during optogenetic manipulation.** Repetitive
935 suprathreshold stimulations induce a progressive increase in WDR response, called the windup
936 effect. **a.** Optogenetic activation of vIPAG SST cells increased the windup coefficient (**, $P <$
937 0.01 , OFF vs. ON – Wilcoxon matched-pairs signed-rank test). **b.** Optogenetic inhibition decreased
938 the windup coefficient (*, $P < 0.05$, OFF vs. ON – Wilcoxon matched-pairs signed-rank test). **c.**
939 Mice expressing GFP in SST vIPAG, optogenetic manipulation of the SST vIPAG had no effect
940 on the windup effect (ns, $P > 0.05$, OFF vs. ON – Wilcoxon matched-pairs signed-rank test).


941
942 **Supplementary Figure 9: Optogenetic manipulation of GFP expressing vIPAG neurons had**
943 **no effect on nociception.** **a.** Single-unit recordings of WDR neurons in the lumbar spinal cord
944 during optogenetic manipulation of GFP expressing SST vIPAG inputs to the RVM (left panel).
945 Light illumination of vIPAG SST inputs to the RVM had no effect in WDR response to both C and
946 A-mediated peripheral fibers stimulation (right panel; ns, $P > 0.05$, Wilcoxon signed-rank test). **b.**
947 Light illumination of vIPAG SST inputs to the RVM did not change the subliminal peripheral
948 stimulation in a supraliminal response (ns, $P > 0.05$, Wilcoxon signed-rank test). **c.** Windup
949 coefficient of WDR cells did not change upon light illumination of vIPAG SST inputs to RVM (ns,
950 $P > 0.05$, Wilcoxon signed-rank test).




Winke et al., Figure 1




Winke et al., Figure 2




Winke et al., Figure 3




Winke et al., Figure 4



Winke et al., Figure 5



Winke et al., Figure 6



Winke et al., Figure 7